Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05462613 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Study acronym: REPROGRAM-02
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 13 to 16v5
  2. Site details revised at 6 of 13 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 7 to 13
    • Start date changed from estimate of Mar 2023 to May 9, 2023
    v3
  4. Start date: Nov 2022 to Mar 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
Trial Details
NCT Number NCT05462613
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 446 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov